

YR0040

Leader in Biomolecular Solutions for Life Science



Human VEGF Monoclonal Antibody Fragment (Fab)

Catalog No.: YR0040

Basic Information

Molecular Weight

48 kDa

Endotoxin

<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

The humanized anti-VEGF-A monoclonal antibody drug Bevacizumab (trade name Avastin, Genentech/Roche) is the first clinically available angiogenesis inhibitor in the United States. The humanized anti-VEGF-A monoclonal antibody fragment (Fab) Ranibizumab (trade name Lucentis, Genentech) is derived from the same parent mouse antibody as bevacizumab. Both antibody drugs produce angiogenesis inhibition and slow the growth of new blood vessels. Ranibizumab is much smaller than the parent complete antibody but shows stronger binding to VEGF-A after affinity maturation. Ranibizumab can also be used to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss. Vascular endothelial growth factor A (VEGF-A) stimulates angiogenesis in a variety of cancers, including colorectal, lung, breast, glioblastoma, kidney, and ovarian cancers.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Ranibizumab Biosimilar

Isotype

Immunogen

Recombinant human VEGF

Recommended Isotype Control(s)

Recommended Dilution Buffer

1×PBS pH 5.3

Contact



www.abclonal.com

Product Information

Production

The research grade Fab protein ranibizumab was produced in the ranibizumab biosimilar E.coli cell line.

Purification

Protein A or G purification

Storage

Store at 2 - 8°C. 2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)